<i id='DCEDC02BDC'><strike id='DCEDC02BDC'><tt id='DCEDC02BDC'><pre id='DCEDC02BDC'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Duchenne breakthrough therapy leaves behind pioneering families 
CMS should re 
How one medical school became remarkably diverse 
New CMS data security rules will hurt Medicare, Medicaid research 
Hollywood unions extend contract negotiations for actors 
As AI regulations shape up, health tech startups beg for clarity 
Virginia high school admissions case could be legal follow 
The woman behind the Dana Farber 
Anesthesiologist group: stop taking Ozempic before surgery 
Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma
Anesthesiologist group: stop taking Ozempic before surgery 
Opioid cravings were reduced by anti 
23andMe had bad news about my health. I wish a person had delivered it 
STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc 
Peter Hotez and the public health issue of online harassment 
